The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era


1Department of Infection and Population Health, University College London, United Kingdom; 2Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland; 3Hospital Clinic-IDIBAPS, University of Barcelona, Spain; 4Academisch Medisch Centrum bij de Universiteit van Amsterdam; 5Stichting HIV Monitoring, Amsterdam, The Netherlands; 6Università Modena, Italy; 7Copenhagen HIV Programme, and 8Department of Infectious Diseases, Copenhagen University Hospital/Righospitalet, Denmark; 8UPMC, Université Paris 06, and 9INSERM, UMR S 843, and 11AP-HP, Hôpital Avicenne, Services des Maladies Infectieuses et Tropicales, Paris, and 12CHU de Bordeaux and INSERM U897, Bordeaux, France; 13Department of Infectious Disease, Robert Koch-Institute, Berlin, Germany; 14Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; 15Department of Infectious Diseases IRCCS San Raffaele, and 16Department of Health Sciences, Institute of Infectious Diseases, Milan, Italy; 17St Stephen’s Clinic, Chelsea and Westminster Hospital, London, United Kingdom; 18Infectious Diseases Unit, Hospital General Universitario de Elche, Universidad Miguel Hernández, Alicante, and 19Centro Superior de Investigación en Salud Pública (CSISP-FISABIO), Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, Spain; 20Competence Network for HIV/AIDS, St Josef-Clinik, Ruhr-University, Bochum, Germany; 21CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris, and 22Epidemiology and Public Health Service, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre, France; 23Department of Infectious Diseases, Hospital Universitario de Basurto, Bilbao, and 24Hospital Universitario Vall d’Hebron, Universitat Autònoma de Barcelona, Spain; 25University of Athens Medical School, University General Hospital “ATTIKON,” Greece; 26University Hospital, Hotel Dieu, Nantes, France; 27Hospital Universitario de Getafe, Madrid, Spain; 28Medizinische Universität Klinik I, University of Bonn, Germany; 29Department of Internal Medicine and Infectious Diseases, Cohnic Hospital, Paris, France; 30University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia, and 31Department of Medical and Surgical Sciences, Unit of Infectious Diseases, University “Magna Graecia,” Catanzaro, Italy; 32AP-HP Public Health Department, INSERM CESP U1018, Université Paris-Sud, Le Kremlin-Bicêtre, France; 33Saint-Pierre Hospital, Brussels, Belgium; 34Medical University Innsbruck, Austria; 35Centre INSERM U897-Epidémiologie Statistique, Université de Bordeaux, ISPED, and 36INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France

(See the HIV/AIDS Major Article by Lesko et al on pages 1027–37 and the Editorial Commentary by Lange on pages 1048–50.)

Background. Few studies consider the incidence of individual AIDS-defining illnesses (ADIs) at higher CD4 counts, relevant on a population level for monitoring and resource allocation.

Methods. Individuals from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) aged ≥14 years with ≥1 CD4 count of ≥200 µL between 1998 and 2010 were included. Incidence rates (per 1000 person-years of follow-up [PYFU]) were calculated for each ADI within different CD4 strata; Poisson regression, using generalized estimating equations and robust standard errors, was used to model rates of ADIs with current CD4 ≥500/µL.

Results. A total of 12,135 ADIs occurred at a CD4 count of ≥200 cells/µL among 207,539 persons with 1,154,803 PYFU. Incidence rates declined from 20.5 per 1000 PYFU (95% confidence interval [CI], 20.0–21.1 per 1000 PYFU) with current CD4 200–349 cells/µL to 4.1 per 1000 PYFU (95% CI, 3.6–4.6 per 1000 PYFU) with current CD4 ≥1000 cells/µL. Persons with a current CD4 of 500–749 cells/µL had a significantly higher rate of ADIs (adjusted incidence rate ratio [aIRR], 1.20; 95% CI, 1.10–1.32), whereas those with a current CD4 of ≥1000

Clinical Infectious Diseases 2013;57(7):1038–47
© The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DOI: 10.1093/cid/cit423
cells/µL had a similar rate (aIRR, 0.92; 95% CI, 0.79–1.07), compared to a current CD4 of 750–999 cells/µL. Results were consistent in persons with high or low viral load. Findings were stronger for malignant ADIs (aIRR, 1.52; 95% CI, 1.25–1.86) than for nonmalignant ADIs (aIRR, 1.12; 95% CI, 1.01–1.25), comparing persons with a current CD4 of 500–749 cells/µL to 750–999 cells/µL.

**Discussion.** The incidence of ADIs was higher in individuals with a current CD4 count of 500–749 cells/µL compared to those with a CD4 count of 750–999 cells/µL, but did not decrease further at higher CD4 counts. Results were similar in patients virologically suppressed on combination antiretroviral therapy, suggesting that immune reconstitution is not complete until the CD4 increases to >750 cells/µL.

**Keywords.** CD4; virologic suppression; cART; AIDS defining illnesses; immune reconstitution.

The decline in AIDS-defining illnesses (ADIs) and deaths following the introduction of combination antiretroviral therapy (cART) in 1996–1997 has been well documented [1–3]. Studies have also described the decline in individual ADIs, such as non-Hodgkin lymphoma, *Pneumocystis jirovecii* pneumonia, *Mycobacterium avium* complex, Kaposi sarcoma, tuberculosis, and cytomegalovirus infections [1, 4–7]. Prior to the introduction of cART, and in antiretroviral-naive patients, the incidence of ADIs according to current CD4 count has been described [8, 9] There is preliminary evidence that the risk of ADIs continues to decrease as CD4 count increases, even at CD4 counts >500 cells/µL [9, 10], but, to our knowledge, there are few studies that have specifically considered the incidence of individual ADIs at higher CD4 counts [10, 11]. Previous work from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) has shown that the risk of a new ADI or death continued to decrease in patients with virological suppression where the current CD4 count was >500 cells/µL, but the study did not report the incidence of individual ADIs or investigate whether there was an additional decrease at higher CD4 counts [12]. Approximately 80% of persons on cART are virologically suppressed [13], but it is also relevant to determine the incidence of ADIs overall and for specific diagnoses on a population level, both for monitoring and for resource allocation. Knowledge of the risk of a specific ADI at a given CD4 lymphocyte count and the identification of a possible threshold of immunodeficiency have important implications for patient management, as well as providing an important reference for the incidence of a wide range of ADIs at higher CD4 counts.

The aims of this study were to describe the incidence of specific ADIs at CD4 counts of ≥200 cells/µL, according to the latest CD4 count across a wide range of CD4 counts using data from COHERE, a European collaboration of HIV cohort studies. Our second objective was to determine the factors associated with developing a new ADI at a CD4 count of ≥500 cells/µL.

**METHODS**

**Patients**

COHERE is a collaboration of 33 cohorts from across Europe. COHERE was established in 2005 and merges data from already established cohorts to conduct epidemiological research on the prognosis of HIV-positive persons where the individual contributing cohorts are not adequately powered. Local ethical committee and/or other regulatory approval were obtained as applicable according to local and/or national regulations in all cohorts unless no such requirement applied to observational studies according to national regulations. Each cohort submits information using the standardized HIV Collaboration Data Exchange Protocol (HICDEP; [14]) to coordinating centers at the Copenhagen HIV Programme (CHIP), Copenhagen, Denmark, or the Institut de Santé Publique d’Épidémiologie et de Développement (ISPED), Bordeaux, France. Data collected and analyzed herein were part of the 2011 merger, and included data from the period 1998–2010. Data collected include information on patient demographics, use of cART, CD4 cell counts, ADIs, and deaths. ADIs were diagnosed using the 1993 classification from the Centers for Disease Control and Prevention [15]. COHERE is part of EuroCOORD, a network of excellence established in 2010 (http://www.eurocoord.net/). Further details about COHERE can be found at www.cphiv.dk and http://etudes.isped.u-bordeaux2.fr/cohere/. All individuals in COHERE aged ≥14 years with at least 1 CD4 count of ≥200 cells/µL measured after 1 January 1998 with some prospective follow-up were included in the analyses, regardless of their current antiretroviral treatment or treatment history.

**Statistical Methods**

Baseline was defined as the first recorded CD4 count ≥200 cells/µL measured after 1 January 1998 (corresponding to the widespread availability of cART); person-years of follow-up (PYFU) were allocated to CD4 count strata (200–349, 350–499, 500–749, 750–999, and ≥1000 cells/µL) and the individual ADIs allocated to the stratum they occurred in. Follow-up was censored when the CD4 count fell below 200 cells/µL (and was subsequently reentered into the analysis if the CD4 count rose to ≥200 cells/µL) or at last CD4 count. Incidence rates were calculated for each individual ADI occurring in >50 individuals, and other diagnoses were combined to create an “other” category. Recurrences of the same ADI were excluded but persons could contribute >1 event to the analysis and moved through CD4 count categories according to their current CD4 count.
Poison regression, using generalized estimating equations and robust standard errors, were used to model rates of a new ADI in persons with a current CD4 ≥500 cells/µL. Baseline for this analysis was the first CD4 count ≥500 cells/µL measured after January 1998. Standard adjustments for other factors included age, sex, HIV transmission group, ethnic origin, HIV RNA load, duration of immune suppression (proportion of follow-up time with CD4 count ≤200 cells/µL, including prior to baseline for this analysis) or of controlled viremia (viral load [VL] <400 copies/mL including time prior to baseline), and starting cART. Within each CD4 count stratum, the current CD4 count was included as a continuous variable to see if there was a trend of an increasing rate of new ADIs at lower CD4 counts within CD4 stratum.

We performed a number of sensitivity analyses to investigate if our results were robust in different populations. We excluded counts within CD4 stratum.

If there was a trend of an increasing rate of new ADIs at lower CD4 count was included as a continuous variable to see if there was a trend of an increasing rate of new ADIs at lower CD4 count had been measured within the previous 6 months. We also repeated the analysis in antiretroviral-naive persons by right-censoring at starting cART, in those with VL ≥200 cells/µL, including prior to baseline for this analysis) or of controlled viremia (viral load [VL] <400 copies/mL including time prior to baseline), and starting cART. Within each CD4 count stratum, the current CD4 count was included as a continuous variable to see if there was a trend of an increasing rate of new ADIs at lower CD4 counts within CD4 stratum.

We performed a number of sensitivity analyses to investigate if our results were robust in different populations. We excluded counts within CD4 stratum.

Of 250,553 individuals included in participating cohorts in COHERE, 24,481 were excluded because they had no CD4 counts recorded of ≥200 cells/µL; a further 218 were excluded because sex or information on date of birth was missing; 1930 were excluded because they were aged <14 years; and 16,385 were excluded because they had no prospective follow-up, leaving 207,539 persons included in the analysis. Characteristics at baseline are shown in Table 1; 149,730 persons were included in the analysis focused on those with CD4 counts ≥500 cells/µL. The most common HIV transmission group was men who have sex with men (MSM). The median CD4 at baseline was 378 cells/µL (interquartile range [IQR], 264–548 cells/µL), and 39,968 (19.3%) had a prior AIDS diagnosis. A total of 12,135 of the ADIs observed occurred at a CD4 count of ≥200 cells/µL. The most common ADI was esophageal candidiasis (n = 1,629 [13.4%]), followed by Kaposi sarcoma (n = 1,323 [10.9%]) and pulmonary tuberculosis (n = 1,263 [10.4%]). The median CD4 count at diagnosis ranged from 314 cells/µL (IQR, 252–450 cells/µL) in persons diagnosed with disseminated Mycobacterium avium complex to 416 cells/µL (IQR, 310–574 cells/µL) in persons diagnosed with recurrent herpes infections. Incidence rates of new ADIs declined from 20.5 per 1000 PYFU (95% confidence interval [CI], 20.0–21.1 per 1000 PYFU) in those with a current CD4 count of 200–349 cells/µL to 4.1 per 1000 PYFU (95% CI, 3.6–4.6 per 1000 PYFU) where current CD4 count was ≥1000 cells/µL. The number of events, PYFU, and event rates within each CD4 count stratum are shown for each ADI in Table 2, ordered from the highest overall incidence to the lowest. Four ADIs—esophageal candidiasis (1.4 [95% CI, 1.3–1.5]), Kaposi sarcoma (1.2 [95% CI, 1.1–1.2]), pulmonary tuberculosis (1.1 [95% CI, 1.0–1.2]), and extrapulmonary tuberculosis (1.1 [95% CI, 1.0–1.1])—had overall incidence rates >1 per 1000 PYFU.

Factors associated with the development of a new ADI at a current CD4 count of ≥500 cells/µL are shown in Table 3. Male and female intravenous drug users had an increased rate of developing a new ADI, whereas male and female heterosexuals had a lower rate. Persons with a current VL >10,000 copies/mL had a higher rate, as did older individuals and those with a higher proportion of follow-up time with a CD4 count <200 cells/µL. A higher proportion of follow-up time with VL <400 copies/mL was associated with a lower rate of new ADIs. Compared to persons with a CD4 count of 750–999 cells/µL, those with a current CD4 count of 500–749 cells/µL had a significantly higher rate of new ADIs (adjusted incidence rate ratio [aIRR], 1.20 [95% CI, 1.10–1.32], P < .0001), whereas those with a CD4 count of ≥1000 cells/µL had a similar rate (aIRR, 0.92 [95% CI, .79–1.07], P = .26). Among persons with a current CD4 of 500–749 cells/µL, a 50-cells/µL-lower CD4 count was associated with a 6% increased rate of a new ADI (aIRR, 1.06 [95% CI, 1.02–1.10], P < .0001), whereas in those with a CD4 count of 750–999 cells/µL, there was no evidence that a lower CD4 count within this stratum was associated with an increased rate (aIRR, 1.01 [95% CI, .96–1.07], P = .72), or in those with a current CD4 of ≥1000 cells/µL (aIRR, 1.00 [95% CI, .98–1.03], P = .86).

We performed several sensitivity analyses; those considering viral suppression or antiretroviral treatment are shown in Figure 1. Results were consistent in antiretroviral-naive patients. There was no evidence that the relationship between current CD4 and ADIs differed according to level of viral suppression (P = .49, test for interaction). Compared to patients with a current CD4 count of 750–999 cells/µL, those with a CD4 count of 500–749 cells/µL had significantly higher rates of new ADIs after adjustment in those with a low (<400 copies/mL)
or high viral load (>400 copies/mL; Figure 1). During the first 6 months of cART, slightly different results were found (Figure 1). After adjustment, compared to patients with a current CD4 of 750–999 cells/µL, there was no increased rate of a new ADI in those with either lower (500–749 cells/µL) or higher current CD4 counts (>1000 cells/µL). Additional sensitivity analyses are shown in Table 4. We removed the first 6 months of follow-up for each individual due to concerns that a significant number of new ADIs might be diagnosed at, or soon after, initial presentation, and found a 19% increased incidence of a new ADI in those with a current CD4 count of 500–749 cells/µL compared to those with a current CD4 count of 750–999 cells/µL (aIRR, 1.19 [95% CI, 1.08–1.32]). In an analysis limited to those with only definitive diagnoses, there was a 22% increased rate in those with a current CD4 count of 500–749 cells/µL (aIRR, 1.22 [95% CI, 1.05–1.41]). This increased rate was somewhat higher for malignant ADIs (aIRR, 1.52 [95% CI, 1.25–1.86]) than for nonmalignant ADIs (aIRR, 1.12 [95% CI, 1.01–1.25]). Adjusting additionally for CD8, missing for approximately 20% of persons, did not alter our findings (Table 4), but CD8 was a predictor of a new ADI; a CD8 count >1000 cells/µL was associated with a higher rate of new ADIs (aIRR, 1.16 [95% CI, 1.06–1.27], P = .0009).

**DISCUSSION**

This analysis included >200 000 HIV-infected individuals with 1 154 803 PYFU while at a current CD4 count of ≥200 cells/µL,
including almost 150,000 persons and >550,000 PYFU with a current CD4 count of ≥500 cells/µL, and described the incidence of the 18 most commonly occurring ADIs in European HIV Cohort studies, across a range of current CD4 stratum, up to and including CD4 counts >1000/µL. Compared to patients with a current CD4 count of 750–999 cells/µL, those with a CD4 count of 500–749 cells/µL had a significantly higher rate of new ADIs, whereas those with current CD4 counts of >1000 cells/µL had a similar incidence. Within CD4 count strata 750–999 cells/µL and ≥1000 cells/µL, there was no evidence of a decreasing incidence of new ADIs within the strata. Highly consistent results were found across a wide range of sensitivity analyses.

The overall rate of new ADIs was low at current CD4 counts ≥500 cells/µL, <6 per 1000 PYFU, compared to a rate of >1000 per 1000 PYFU at current CD4 counts <50 cells/µL. We found an increased rate of new ADIs at a current CD4 count of 500–749 cells/µL compared to 750–999 cells/µL or higher but no evidence of any association between CD4 count and incidence of new ADIs within the 750–999 cells/µL or ≥1000 cells/µL category, with quite narrow confidence intervals, suggesting that HIV-infected patients with a CD4 count ≥750 cells/µL have no further reduction in risk of new ADIs with higher CD4 counts. We adjusted for other markers of immunological function, such as CD8, CD4 percentage, and CD8 percentage, in the subset of individuals with data, with consistent results (data not shown). There are a number of studies that have shown that having a current CD4 count ≥500 cells/µL is beneficial in terms of a combined endpoint of a new ADI and death [9, 10, 12, 16], although these studies have been more limited by power and have not split CD4 count stratum ≥500 cells/µL as in this current analysis.

Our results were consistent across a range of sensitivity analyses, and were similar between antiretroviral-naïve persons and those who were or were not virologically suppressed, although we were unable to say whether the ADIs experienced were
similar between those on and off cART or with and without virologic suppression. The relationship between current CD4 and ADIs differed slightly during the first 6 months of cART, with no increased rate seen in those with a current CD4 count of 500–749 cells/µL compared to 750–999 cells/µL. The reasons for this are unclear, but could reflect the increased rate of ADIs in relation to high viremia irrespective of CD4 count during the initial period after starting cART, compared to patients who have been on cART for longer [6].

Our findings were stronger for malignant compared to nonmalignant ADIs. The strength of the association was similar for Kaposi sarcoma and non-Hodgkin lymphoma (data not

<table>
<thead>
<tr>
<th>Factor</th>
<th>Univariate Analysis</th>
<th>Multivariate Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IRR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Current CD4, cells/µL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;750</td>
<td>1.33</td>
<td>1.22–1.46</td>
</tr>
<tr>
<td>750–999</td>
<td>1.00</td>
<td>. . .</td>
</tr>
<tr>
<td>≥1000</td>
<td>0.85</td>
<td>.74–.98</td>
</tr>
<tr>
<td>HIV transmission group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSM</td>
<td>1.00</td>
<td>. . .</td>
</tr>
<tr>
<td>Male IDU</td>
<td>1.13</td>
<td>.99–1.28</td>
</tr>
<tr>
<td>Female IDU</td>
<td>1.50</td>
<td>1.28–1.77</td>
</tr>
<tr>
<td>Male heterosexual</td>
<td>0.86</td>
<td>.76–.97</td>
</tr>
<tr>
<td>Female heterosexual</td>
<td>0.86</td>
<td>.77–.95</td>
</tr>
<tr>
<td>Male other</td>
<td>0.87</td>
<td>.72–1.04</td>
</tr>
<tr>
<td>Female other</td>
<td>1.14</td>
<td>.90–1.43</td>
</tr>
<tr>
<td>Country of origin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Developed</td>
<td>1.00</td>
<td>. . .</td>
</tr>
<tr>
<td>Africa</td>
<td>1.02</td>
<td>.88–1.19</td>
</tr>
<tr>
<td>Other</td>
<td>0.97</td>
<td>.79–1.19</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.03</td>
<td>.95–1.12</td>
</tr>
<tr>
<td>Ethnic origin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>1.00</td>
<td>. . .</td>
</tr>
<tr>
<td>Other</td>
<td>1.02</td>
<td>.88–1.15</td>
</tr>
<tr>
<td>Unknown</td>
<td>0.85</td>
<td>.78–.92</td>
</tr>
<tr>
<td>Current VL, copies/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400</td>
<td>1.00</td>
<td>. . .</td>
</tr>
<tr>
<td>400–10 000</td>
<td>1.28</td>
<td>1.16–1.42</td>
</tr>
<tr>
<td>&gt;10 000</td>
<td>2.60</td>
<td>2.36–2.85</td>
</tr>
<tr>
<td>Baseline AIDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes vs no</td>
<td>1.32</td>
<td>1.20–1.45</td>
</tr>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per year later</td>
<td>1.04</td>
<td>1.03–1.06</td>
</tr>
<tr>
<td>Baseline cART</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes vs no</td>
<td>0.88</td>
<td>.82–.95</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per 10 y older</td>
<td>1.03</td>
<td>.99–1.08</td>
</tr>
<tr>
<td>Follow-up CD4 ≤ 200*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per 10% longer</td>
<td>1.22</td>
<td>1.14–1.31</td>
</tr>
<tr>
<td>Follow-up VL &lt; 400*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per 10% longer</td>
<td>0.91</td>
<td>.90–.92</td>
</tr>
</tbody>
</table>

Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IDU, intravenous drug user; IRR, incidence rate ratio; MSM, men who have sex with men; VL, viral load.

* Included as time-updated variable and includes follow-up time prior to baseline.
shown) while the model for cervical cancer did not converge due to insufficient numbers. Kaposi sarcoma is diagnosed across a wide range of CD4 counts independent of CD4 nadir [17]. Most persons in this study had started cART at low CD4 count levels [18], and the onset of non-Hodgkin lymphoma soon after cART initiation might be indicative of immune reconstitution syndrome [19] or subclinical disease. COHERE is an observational study, and confounding by indication is likely to play a significant role. Our findings should not therefore be extrapolated to the “when to start cART” question. In time, the randomized clinical trial START (Strategic Timing of Initiation of Antiretroviral Therapy), with both AIDS and non-AIDS clinical endpoints, will provide unbiased estimates of whether cART is of net clinical benefit to persons commencing therapy at higher CD4 counts. The clinical benefits of cART at higher CD4 counts, where the reduction in risk is statistically but not necessarily clinically significant, need to be balanced against the long-term potential costs and risks of antiretroviral therapy, such as resistance development and adverse events including cardiovascular and renal disease, and malignancies that may add to other comorbidities associated with aging, immune activation, and HIV-related inflammation [20–22].

Other predictors of a new ADI included HIV transmission group and HIV load, as previously reported [23–25]. Both proportion of follow-up time with advanced immunodeficiency (CD4 count ≤200 cells/µL) and with controlled viremia (<400 copies/mL) were independent predictors of a new ADI. Viremia copy-years, a different way of measuring exposure to replicating virus, has been shown to predict mortality independent of current CD4 counts among those on cART [26]. This supports findings from the SMART trial, which also showed that the proportion of follow-up time with detectable viremia was, as expected, higher in persons who interrupted vs continued cART, and that the group that interrupted cART had an increased risk of both ADI as well as various types of organ disease [27]. One explanation is that cumulative exposure to uncontrolled HIV replication is a surrogate for cumulative immune system activation, inflammation, and depletion of lymphoid organs from central memory and naive CD4+ T cells exhausting the immune system [26, 28, 29]. Duration of immune deficiency as a marker of disease progression has been investigated in previous studies with varying degrees of immunodeficiency, endpoints, and results [30–32]. It is likely that circulating CD4 cells are a good but not a perfect marker of the immune capacity in HIV infection. In addition, duration of immunodeficiency likely captures extra data not measured through the CD4 count due to its variability [33] or differences in frequency of measurement between persons.

This study has a number of limitations. We were not able to adjust for hepatitis B or C status, or prior use of disease-specific prophylaxis, as the data were quite limited. The incidence of new ADIs at higher CD4 counts was extremely low, and our results provide some evidence that there is a small increased risk of a new ADI at CD4 counts of 500–750 cells/µL, but not

![Figure 1.](cid2013:57_167_hiv/aids)
above this level. Although COHERE includes many of the European observational cohorts, some regions, such as Eastern Europe, are not well represented [18] and the incidence of specific ADIs in these regions may well differ from that presented here [34]. In addition, cohorts have a range of quality assurance systems, and we did not use case verification for any ADIs.

Even small differences in reporting of ADIs could change the incidence rates in these rare events considerably. COHERE does not have complete information on non-AIDS events, and we were unable to assess the relationship between non-AIDS events and high CD4 counts, which form a significant proportion of morbidity and mortality in HIV-positive persons [35].
In conclusion, the incidence of specific ADIs varied widely among persons with current CD4 counts 200–499 cells/µL and was generally low among all persons at higher CD4 counts. Despite this low rate of new ADIs at current CD4 counts ≥500 cells/µL, the rate was increased by 20% when compared to those with a current CD4 of 750–999 cells/µL, whereas there were no further significant reductions in ADIs at higher CD4 counts. Results were similar in those with viral suppression and stronger for malignant than nonmalignant events, suggesting that immune-mediated mechanisms other than those induced by HIV replication alone are responsible for this increased rate. Persons with HIV infection are not fully immune reconstituted until the CD4 count increases to >750 cells/µL.

Notes

Financial support. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group is supported by the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), France; HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Denmark. COHERE receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under EuroCoord grant agreement number 260694. A list of the funders of the study can be found on the national coordinating center websites at http://www.cphiv.dk/COHERE/tabid/295/Default.aspx and http://etudes.isped.u-bordeaux2.fr/cohere.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

Appendix

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group

Analysis and Writing Committee

The Opportunistic Infections Project Team

COHERE Steering Committee

Steering Committee—contributing cohorts: Robert Zangerle (AHIVCOS), Antonios Papadopoulos (AMACS), Josiane Warszawski (ANRS CO1 EPF/ANRS CO11 OBSERVatoire EPF), Laurence Meyer (ANRS CO2 SEROCO and ANRS CO6 PRIMO), Sylvie Ayayi (ANRS CO3 AQUITAINE), Sophie Abgrall (ANRS CO4 FHDH), François Raffi (ANRS CO8 Copilote), Peter Reiss (ATHENA), Barbara Bartmeyer (CASCADE), Brian Gazzard (CHIC), Jurgen Rockstroh (Cologne Bonn), Félix Gutierrez (Co-RIS), Pere Soler-Palacin (Co-RI Spe Cat), Niels Obel (Danish HIV Cohort), Amanda Mocroft (EuroSIDA), Ole Kirk (EuroSIDA), Isabel Hurtado (GEMES-Haemo), Dominique Salmon (HEPAVIH), Antonella d’Arminio Monforte (ICONA), Klaus Jansen (Kompnet), José Ramos (Madrid Cohort), Carlo Torti (MASTER), Cristina Mussini (MODENA), Jose M. Miró (PISCIS), Antonella Castagna (San Raffaele), Hansjakob Furrer (SHCS), Dominique Braun (SHCS), Stephane de Wit (St. Pierre Cohort), Pepa Munoz (VACH).

Paediatric cohort representatives: Ali Judd, Josiane Warszawski.

European AIDS Treatment Group: David Haerry.

Executive committee:
Ian Weller (Chair, University College London), Jordi Casabona (PISCIS), Dominique Costagliola (FHDH), Antonella d’Arminio Monforte (ICONA), Manuel Battegay (MoCHIV), Maria Prins (CASCADE), Frank de Wolf (ATHENA), Jesper Grarup (Head of Copenhagen Regional Coordinating Centre), Genevieve Chene (Head, Bordeaux Regional Coordinating Centre).

Regional coordinating centres:
Bordeaux RCC cohorts: Céline Colin, Christine Schwimmer, Guillaume Touzeau; Copenhagen RCC cohorts: Jesper Kjaer, Maria Campbell.

Project leaders and statistical analysis: